Henlius Speeds Up Efforts On Ophthalmic Bevacizumab
Phase III Trial Begins As Chinese Firm Works With Partner Essex On Global Filings
Shanghai Henlius Biotech has revealed the latest update on its proposed ophthalmic version of biosimilar bevacizumab, with a global Phase III trial beginning as the firm also pursues international filings with partner Essex Bio-Technology.
